Mounjaro
Largest revenue line; Q2 2026 revenue $9.94B.
The numbers
What it is
Tirzepatide injection for type 2 diabetes, a dual GIP and GLP-1 receptor agonist. It is Lilly's largest product and is also sold outside the US.↗ source
Why it matters to the stock. Mounjaro's volume and price set the tone for the whole company, and it is the main read-through for Lilly's incretin franchise and rival GLP-1 pricing.
News
Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B
Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices.
Lilly's Q2 2026 revenue rose 48%; revenue guidance raised to $85B-$87B
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48%, with Mounjaro up 91% and Zepbound up 46%.
Michigan Supreme Court reverses appeals ruling in Lilly insulin pricing case
Lilly's quarterly report says the Michigan Supreme Court in July 2026 reversed a Michigan Court of Appeals decision in the insulin pricing litigation.
Lilly's Q1 2026 revenue rose 56%; full-year guidance raised
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56%, mainly from volume growth partly offset by lower realized prices.
Lilly's Q4 2025 revenue rose 43%; 2026 guidance set at $80B-$83B
Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43% from a year earlier, driven by volume growth for Mounjaro and Zepbound.